There was no apparent benefit to continuing oral anticoagulants compared with interruption in patients undergoing transcatheter aortic valve implantation (TAVI), according to late-breaking research presented in a Hot Line ...
Sep 3, 2024
0
0
A combined subgroup analysis of the similar trials NOAH—AFNET 6 and ARTESiA has revealed that patients with device-detected atrial fibrillation and concomitant vascular disease are at higher risk of stroke and cardiovascular ...
Sep 2, 2024
0
0
Using artificial intelligence (AI) to aid clinical decision making in identifying and managing myocardial infarction (MI; heart attack) in patients presenting to the emergency department (ED) with suspected cardiac conditions ...
Sep 2, 2024
0
0
Long-term use of beta-blockers in patients with myocardial infarction and preserved heart function does not significantly change quality of life or well-being compared to no beta-blockers. This is according to a study from ...
Sep 2, 2024
0
0
An invasive strategy vs. optimal medical therapy alone after a non-ST-elevation myocardial infarction (NSTEMI) in older adults did not affect the combined risk of cardiovascular death or MI, although non-fatal MIs and subsequent ...
Sep 2, 2024
0
0
Using optimal coherence tomography (OCT) to guide stent implantation during percutaneous coronary intervention (PCI) in patients with complex coronary lesions significantly improves survival and reduces adverse cardiovascular ...
Sep 2, 2024
0
0
In two trials, one in frail elderly patients, evening administration of BP-lowering medications had no clinical benefits over morning administration, according to late-breaking research presented in a Hot Line session August ...
Sep 2, 2024
0
0
No-touch graft harvesting did not appear to be beneficial compared with the conventional technique for coronary artery bypass grafting (CABG), according to late-breaking research presented in a Hot Line session August 31 ...
Sep 2, 2024
0
0
Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation (AF) and stable ...
Sep 2, 2024
0
0
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global ...
Sep 2, 2024
0
0
